A pre- and post-biopsy analysis of endocrine treated breast cancer has demonstrated that only the post-treatment tumour Ki67 (at 2 weeks) was predictive of response to endocrine therapy, whereas baseline Ki67 was not (Dowsett et al, 2007). This evidence concerns the gene MKI67 and breast carcinoma.